Zepbound cleared for sleep apnea

Obstructive sleep apnea is a disorder in which the upper airway repeatedly collapses during sleep, cutting off breathing for seconds at a time. On December 20, 2024, the Food and Drug Administration approved Zepbound, the brand name for tirzepatide, as the first drug for moderate to severe obstructive sleep apnea in adults with obesity. (fda.gov) The approval covers adults with obesity and moderate to severe disease, and the label says the drug should be used with a reduced-calorie diet and increased physical activity. Zepbound is given as a once-weekly injection. (fda.gov; accessdata.fda.gov) The Food and Drug Administration based the decision on two randomized trials that enrolled 469 adults over 52 weeks. One trial studied people who could not or would not use positive airway pressure, and the other studied people who were already using positive airway pressure. (fda.gov; medical.lilly.com) Doctors track sleep apnea with the apnea-hypopnea index, a count of breathing disruptions per hour of sleep. In the New England Journal of Medicine report on SURMOUNT-OSA, tirzepatide cut that index by 25.3 events per hour in one trial and 29.3 in the other, versus 5.3 and 5.5 with placebo. (nejm.org) The same study found average body-weight reductions of 16.1 percent and 17.3 percent with tirzepatide, compared with 1.6 percent and 2.3 percent with placebo. The paper also reported lower oxygen-deprivation burden and lower systolic blood pressure in the tirzepatide groups. (nejm.org) Obesity and sleep apnea often reinforce each other, because extra tissue around the neck and airway can make collapse during sleep more likely. The American Academy of Sleep Medicine says excess body weight is a major risk factor for obstructive sleep apnea. (aasm.org) Older treatment is still standard care for many patients. The American Academy of Sleep Medicine recommends positive airway pressure, which uses pressurized air through a mask to keep the airway open during sleep, for adults with obstructive sleep apnea. (aasm.org) The Food and Drug Administration said the most common side effects in the sleep apnea studies were nausea, diarrhea, vomiting, constipation, abdominal pain, injection-site reactions, fatigue, allergic reactions, burping, hair loss, and gastroesophageal reflux disease. The label also carries warnings about risks including thyroid C-cell tumors in rats, pancreatitis, gallbladder problems, hypoglycemia when used with certain diabetes drugs, kidney injury, diabetic retinopathy in patients with type 2 diabetes, suicidal behavior or thinking, and pulmonary aspiration during general anesthesia or deep sedation. (fda.gov; accessdata.fda.gov) The approval also extends a broader shift in how these drugs are being used beyond weight loss alone. By April 2026, tirzepatide and similar medicines were already being studied or used across obesity-related conditions that include cardiovascular disease, kidney disease, and other long-term complications. (pharmacytimes.com) For patients with obesity and sleep apnea, the immediate change is simple: there is now a drug option on top of masks, diet, and exercise. Doctors still have to decide, patient by patient, whether weight-loss treatment, positive airway pressure, or both fit the case in front of them. (fda.gov; aasm.org)